Arlene O Siefker-Radtke, MD

Peer-Reviewed Articles

1. Feils AS, Erbe AK, Birstler J, Kim K, Hoch U, Currie SL, Nguyen T, Yu D, Siefker-Radtke AO, Tannir N, Tolaney SM, Diab A, Sondel PM. Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial. Cancer Immunol Immunother 72(7):2099-2111, 2023. e-Pub 2023. PMID: 36823323.
2. Alhalabi O, Zhu Y, Hamza A, Qiao W, Lin Y, Wang RM, Shah AY, Campbell MT, Holla V, Kamat A, Wang WL, Wang J, Chen J, Meng J, Zhang M, Bondaruk J, Titus M, Genovese G, Czerniak BA, Shaw KR, Meric-Bernstam F, Guo CC, Logothetis CJ, Siefker-Radtke A, Msaouel P, Wang L, Liu J, Gao J. Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer. Eur Urol Oncol 6(2):228-232, 2023. e-Pub 2021. PMID: 34789422.
3. Siefker-Radtke AO, Necchi A, Park SH, García-Donas J, Huddart RA, Burgess EF, Fleming MT, Rezazadeh Kalebasty A, Mellado B, Varlamov S, Joshi M, Duran I, Tagawa ST, Zakharia Y, Qi K, Akapame S, Triantos S, O'Hagan A, Loriot Y. Management of Fibroblast Growth Factor Inhibitor Treatment-emergent Adverse Events of Interest in Patients with Locally Advanced or Metastatic Urothelial Carcinoma. Eur Urol Open Sci 50:1-9, 2023. e-Pub 2023. PMID: 37101768.
4. Rezazadeh Kalebasty A, Benjamin DJ, Loriot Y, Papantoniou D, Siefker-Radtke AO, Necchi A, Naini V, Carcione JC, Santiago-Walker A, Triantos S, Burgess EF. Outcomes of Patients with Advanced Urothelial Carcinoma after Anti-programmed Death-(ligand) 1 Therapy by Fibroblast Growth Factor Receptor Gene Alteration Status: An Observational Study. Eur Urol Open Sci 47:48-57, 2023. e-Pub 2022. PMID: 36601039.
5. Siefker-Radtke AO, Cho DC, Diab A, Sznol M, Bilen MA, Balar AV, Grignani G, Puente E, Tang L, Chien D, Hoch U, Choudhury A, Yu D, Currie SL, Tagliaferri MA, Zalevsky J, Hurwitz ME, Tannir NM. Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02. Eur Urol 82(4):365-373, 2022. e-Pub 2022. PMID: 35643589.
6. Labbate CV, Hensley PJ, Miest TS, Qiao W, Adibi M, Shah AY, Chery L, Papadopoulos J, Siefker-Radtke AO, Gao J, Guo CC, Czerniak BA, Navai N, Kamat AM, Dinney CP, Campbell MT, Matin SF. Longitudinal GFR trends after neoadjuvant chemotherapy prior to nephroureterectomy for upper tract urothelial carcinoma. Urol Oncol 40(10):454.e17-454.e23, 2022. e-Pub 2022. PMID: 35961847.
7. Peng J, Sridhar S, Siefker-Radtke AO, Selvarajah S, Jiang DM. Targeting the FGFR Pathway in Urothelial Carcinoma: the Future Is Now. Curr Treat Options Oncol 23(9):1269-1287, 2022. e-Pub 2022. PMID: 35962938.
8. Zaleski MP, Chen H, Roy-Chowdhuri S, Patel KP, Luthra R, Routbort MJ, Kamat AM, Gao J, Siefker-Radtke A, Czerniak B, Guo CC. Distinct Gene Mutations Are Associated With Clinicopathologic Features in Urachal Carcinoma. Am J Clin Pathol 158(2):263-269, 2022. e-Pub 2022. PMID: 35467000.
9. Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chan K, Chang S, Friedlander T, Greenberg RE, Guru KA, Herr HW, Hoffman-Censits J, Kishan A, Kundu S, Lele SM, Mamtani R, Margulis V, Mian OY, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Parikh M, Patterson A, Plimack ER, Pohar KS, Preston MA, Richards K, Sexton WJ, Siefker-Radtke AO, Tollefson M, Tward J, Wright JL, Dwyer MA, Cassara CJ, Gurski LA. NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022. J Natl Compr Canc Netw 20(8):866-878, 2022. PMID: 35948037.
10. Siefker-Radtke AO, Loriot Y. Erdafitinib for locally advanced or metastatic urothelial carcinoma. Am J Health Syst Pharm 79(11):824-825, 2022. e-Pub 2022. PMID: 35147178.
11. Adibi M, McCormick B, Economides MP, Petros F, Xiao L, Guo C, Shah A, Kamat AM, Dinney C, Navai N, Gao J, Siefker-Radtke A, Matin SF, Campbell MT. Five and Ten-Year Outcomes of Neoadjuvant Chemotherapy and Surgery for High-Risk Upper Tract Urothelial Carcinoma. Clin Genitourin Cancer 20(2):176-182, 2022. e-Pub 2021. PMID: 35039231.
12. Alhalabi O, Chen J, Zhang Y, Lu Y, Wang Q, Ramachandran S, Tidwell RS, Han G, Yan X, Meng J, Wang R, Hoang AG, Wang WL, Song J, Lopez L, Andreev-Drakhlin A, Siefker-Radtke A, Zhang X, Benedict WF, Shah AY, Wang J, Msaouel P, Zhang M, Guo CC, Czerniak B, Behrens C, Soto L, Papadimitrakopoulou V, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee J, Roth J, Swisher S, Wistuba I, Heymach J, Wang J, Campbell MT, Efstathiou E, Titus M, Logothetis CJ, Ho TH, Zhang J, Wang L, Gao J. MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers. Nat Commun 13(1):1797, 2022. e-Pub 2022. PMID: 35379845.
13. Tannir NM, Cho DC, Diab A, Sznol M, Bilen MA, Balar AV, Grignani G, Puente E, Tang L, Chien D, Hoch U, Choudhury A, Yu D, Currie SL, Tagliaferri MA, Zalevsky J, Siefker-Radtke AO, Hurwitz ME. Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study. J Immunother Cancer 10(4), 2022. PMID: 35444058.
14. Alhalabi O, Hahn AW, Msaouel P, Meric-Bernstam F, Wilson N, Naing A, Piha-Paul S, Janku F, Pant S, Yap TA, Hong DS, Fu S, Karp D, Beltran K, Campbell E, Le H, Campbell MT, Shah A, Tannir NM, Siefker-Radtke A, Gao J, Roszik J, Subbiah V. Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials. Clin Genitourin Cancer 20(1):e16-e24, 2022. e-Pub 2021. PMID: 34362693.
15. Siefker-Radtke AO, Necchi A, Park SH, García-Donas J, Huddart RA, Burgess EF, Fleming MT, Rezazadeh Kalebasty A, Mellado B, Varlamov S, Joshi M, Duran I, Tagawa ST, Zakharia Y, Akapame S, Santiago-Walker AE, Monga M, O'Hagan A, Loriot Y, BLC2001 Study Group. Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study. Lancet Oncol 23(2):248-258, 2022. e-Pub 2022. PMID: 35030333.
16. Hensley PJ, Bree KK, Campbell MT, Alhalabi O, Kokorovic A, Miest T, Nogueras-Gonzalez GM, Gao J, Siefker-Radtke AO, Guo CC, Navai N, Dinney CP, Kamat AM. Progression of Disease after BCG Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy. J Urol 206(5):101097JU0000000000001943, 2021. e-Pub 2021. PMID: 34184926.
17. Hensley PJ, Bree KK, Campbell MT, Alhalabi O, Kokorovic A, Miest T, Nogueras-Gonzalez GM, Gao J, Siefker-Radtke AO, Guo CC, Navai N, Dinney CP, Kamat AM. Reply by Authors. J Urol 206(5):101097JU000000000000194302, 2021. e-Pub 2021. PMID: 34372685.
18. Alhalabi, Omar; Campbell, Matthew T.; Xiao, Lianchun; Adriazola, Ana C.; Wilson, Nathaniel R.; Siefker-Radtke, Arlene O.; Corn, Paul G.; Zurita, Amado; Jonasch, Eric; Gao, Jianjun; Adibi, Mehrad; Kamat, Ashish M.; Navai, Neema; Pisters, Louis L.; Dinney, Colin; Matin, Surena F.; Shah, Amishi Y.. Multimodal kidney-preserving approach in localised and locally advanced high-risk upper tract urothelial carcinoma. BJUI Compass, 2021.
19. Han G, Yang G, Hao D, Lu Y, Thein K, Simpson BS, Chen J, Sun R, Alhalabi O, Wang R, Dang M, Dai E, Zhang S, Nie F, Zhao S, Guo C, Hamza A, Czerniak B, Cheng C, Siefker-Radtke A, Bhat K, Futreal A, Peng G, Wargo J, Peng W, Kadara H, Ajani J, Swanton C, Litchfield K, Ahnert JR, Gao J, Wang L. 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. Nat Commun 12(1):5606, 2021. e-Pub 2021. PMID: 34556668.
20. Galsky MD, Hoimes CJ, Necchi A, Shore N, Witjes JA, Steinberg G, Bedke J, Nishiyama H, Fang X, Kataria R, Sbar E, Jia X, Siefker-Radtke A. Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303. Future Oncol 17(24):3137-3150, 2021. e-Pub 2021. PMID: 34008425.
21. Msaouel P, Oromendia C, Siefker-Radtke AO, Tannir NM, Subudhi SK, Gao J, Wang Y, Siddiqui BA, Shah AY, Aparicio AM, Campbell MT, Zurita AJ, Shaw LK, Lopez LP, McCord H, Chakraborty SN, Perales J, Lu C, Van Alstine ML, Elashoff M, Logothetis C. Evaluation of Technology-Enabled Monitoring of Patient-Reported Outcomes to Detect and Treat Toxic Effects Linked to Immune Checkpoint Inhibitors. JAMA Netw Open 4(8):e2122998, 2021. e-Pub 2021. PMID: 34459906.
22. Siddiqui BA, Gheeya JS, Goswamy R, Bathala TK, Surasi DS, Gao J, Shah A, Campbell MT, Msaouel P, Goswami S, Wang J, Zurita AJ, Jonasch E, Corn PG, Aparicio AM, Siefker-Radtke AO, Sharma P, Subudhi SK, Tannir N. Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events. J Immunother Cancer 9(7), 2021. PMID: 34326169.
23. Knowles M, Dyrskjøt L, Heath EI, Bellmunt J, Siefker-Radtke AO. Metastatic urothelial carcinoma. Cancer Cell 39(5):583-585, 2021. PMID: 33974855.
24. McGregor BA, Campbell MT, Xie W, Farah S, Bilen MA, Schmidt AL, Sonpavde GP, Kilbridge KL, Choudhury AD, Mortazavi A, Shah AY, Venkatesan AM, Bubley GJ, Siefker-Radtke AO, McKay RR, Choueiri TK. Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies. Cancer 127(6):840-849, 2021. e-Pub 2020. PMID: 33216356.
25. Alhalabi O, Hahn AW, Msaouel P, Andreev-Drakhlin AY, Meric-Bernstam F, Naing A, Piha-Paul S, Filip J, Pant S, Yap TA, Hong DS, Fu S, Karp D, Campbell E, Le H, Campbell MT, Shah AY, Tannir NM, Siefker-Radtke AO, Gao J, Roszik J, Subbiah V. Molecular profiling of metastatic bladder cancer early-phase clinical trial participants predicts patient outcomes. Mol Cancer Res 19(3):395-402, 2021. e-Pub 2020. PMID: 33323389.
26. Huddart RA, Siefker-Radtke AO, Balar AV, Bilen MA, Powles T, Bamias A, Castellano D, Khalil MF, Van Der Heijden MS, Koshkin VS, Pook DW, Özgüroglu M, Santiago L, Zhong B, Chien D, Lin W, Tagliaferri MA, Loriot Y. PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer. Future Oncol 17(2):137-149, 2021. e-Pub 2020. PMID: 32938232.
27. Viscuse PV, Marques-Piubelli ML, Heberton MM, Parra ER, Shah AY, Siefker-Radtke A, Gao J, Goswami S, Ivan D, Curry JL, Campbell MT. Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction. Front Oncol 11:621591, 2021. e-Pub 2021. PMID: 33747934.
28. Gao J, Navai N, Alhalabi O, Siefker-Radtke A, Campbell MT, Tidwell RS, Guo CC, Kamat AM, Matin SF, Araujo JC, Shah AY, Msaouel P, Corn P, Wang J, Papadopoulos JN, Yadav SS, Blando JM, Duan F, Basu S, Liu W, Shen Y, Zhang Y, Macaluso MD, Wang Y, Chen J, Zhang J, Futreal A, Dinney C, Allison JP, Goswami S, Sharma P. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med. e-Pub 2020. PMID: 33046869.
29. Yang G, Bondaruk J, Cogdell D, Wang Z, Lee S, Lee JG, Zhang S, Choi W, Wang Y, Liang Y, Wang G, Wang Y, Yao H, Dadhania V, Gao J, Logothetis C, Siefker-Radtke A, Kamat A, Dinney C, Theodorescu D, Kimmel M, Wei P, Guo CC, Weinstein JN, McConkey DJ, Czerniak B. Urothelial-to-Neural Plasticity Drives Progression to Small Cell Bladder Cancer. iScience 23(6):101201, 2020. e-Pub 2020. PMID: 32521509.
30. Galsky MD, Saci A, Szabo PM, Han GC, Grossfeld G, Collette S, Siefker-Radtke A, Necchi A, Sharma P. Nivolumab in Patients with Advanced Platinum-Resistant Urothelial Carcinoma: Efficacy, Safety, and Biomarker Analyses with Extended Follow-up from CheckMate 275. Clin Cancer Res. e-Pub 2020. PMID: 32532789.
31. Alhalabi O, Campbell M, Shah A, Siefker-Radtke A, Gao J. Emerging treatments in advanced urothelial cancer. Curr Opin Oncol 32(3):232-239, 2020. PMID: 32209822.
32. Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chang S, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Guzzo T, Herr HW, Hoffman-Censits J, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Preston MA, Sexton WJ, Siefker-Radtke AO, Tward J, Wright JL, Gurski LA, Johnson-Chilla A. Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 18(3):329-354, 2020. PMID: 32135513.
33. Schmidt AL, Siefker-Radtke A, McConkey D, McGregor B. Renal Cell and Urothelial Carcinoma: Biomarkers for New Treatments. Am Soc Clin Oncol Educ Book 40:1-11, 2020. PMID: 32379987.
34. Kamoun A, de Reyniès A, Allory Y, Sjödahl G, Robertson AG, Seiler R, Hoadley KA, Groeneveld CS, Al-Ahmadie H, Choi W, Castro MAA, Fontugne J, Eriksson P, Mo Q, Kardos J, Zlotta A, Hartmann A, Dinney CP, Bellmunt J, Powles T, Malats N, Chan KS, Kim WY, McConkey DJ, Black PC, Dyrskjøt L, Höglund M, Lerner SP, Real FX, Radvanyi F, Aine M, Bernard-Pierrot I, Czerniak B, Gibb EA, Kim J, Kwiatkowski DJ, Lebret T, Liedberg F, Siefker-Radtke AA, Sirab N, Taber A, Weinstein JN. Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer: A Step in the Right Direction but Still a Long Way To Go. Eur Urol. In press. Eur Urol. e-Pub 2020. PMID: 32037144.
35. Wang L, Gong Y, Saci A, Szabo PM, Martini A, Necchi A, Siefker-Radtke A, Pal S, Plimack ER, Sfakianos JP, Bhardwaj N, Horowitz A, Farkas AM, Mulholland D, Fischer BS, Oh WK, Sharma P, Zhu J, Galsky MD. Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer. Eur Urol 76(5):599-603, 2019. e-Pub 2019. PMID: 31272788.
36. Loriot Y, Necchi A, Park SH, Garcia-Donas J, Huddart R, Burgess E, Fleming M, Rezazadeh A, Mellado B, Varlamov S, Joshi M, Duran I, Tagawa ST, Zakharia Y, Zhong B, Stuyckens K, Santiago-Walker A, De Porre P, O'Hagan A, Avadhani A, Siefker-Radtke AO, BLC2001 Study Group. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. N Engl J Med 381(4):338-348, 2019. PMID: 31340094.
37. Duplisea JJ, Petros FG, Li R, Fellman B, Guo CC, Czerniak BA, Siefker-Radtke AO, Araujo JC, Dinney CPN, Matin SF. Outcomes of nonmetastatic micropapillary variant upper tract urothelial carcinoma. Urol Oncol 37(6):354.e19-354.e26, 2019. e-Pub 2019. PMID: 30777393.
38. Ohyama C, Kojima T, Kondo T, Naya Y, Inoue T, Tomita Y, Eto M, Hisasue S, Uemura H, Obara W, Kikuchi E, Sharma P, Galsky MD, Siefker-Radtke A, Grossfeld G, Collette S, Gooden K, Kimura G. Nivolumab in patients with unresectable locally advanced or metastatic urothelial carcinoma: CheckMate 275 2-year global and Japanese patient population analyses. Int J Clin Oncol. e-Pub 2019. PMID: 31218529.
39. Alhalabi O, Rafei H, Shah A, Siefker-Radtke A, Campbell M, Gao J. Targeting advanced urothelial carcinoma-developing strategies. Curr Opin Oncol 31(3):207-215, 2019. PMID: 30844889.
40. Sharma P, Siefker-Radtke A, de Braud F, Basso U, Calvo E, Bono P, Morse MA, Ascierto PA, Lopez-Martin J, Brossart P, Rohrberg K, Mellado B, Fischer BS, Meadows-Shropshire S, Abdel Saci , Callahan MK, Rosenberg J. Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results. J Clin Oncol:JCO1900538. e-Pub 2019. PMID: 31100038.
41. Merseburger AS, Apolo AB, Chowdhury S, Hahn NM, Galsky MD, Milowsky MI, Petrylak D, Powles T, Quinn DI, Rosenberg JE, Siefker-Radtke A, Sonpavde G, Sternberg CN. SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer. World J Urol 37(1):95-105, 2019. e-Pub 2018. PMID: 30238401.
42. Wang G, Xiao L, Zhang M, Kamat AM, Siefker-Radtke AO, Dinney CP, Czerniak B, Guo CC. Small cell carcinoma of the urinary bladder: a Clinicopathologic and Immunohistochemical analysis of 81 cases. Hum Pathol 79:57-65, 2018. e-Pub 2018. PMID: 29763719.
43. Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak DP, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Tward J, Wile G, Johnson-Chilla A, Dwyer MA, Gurski LA. NCCN Guidelines Insights: Bladder Cancer, Version 5.2018. J Natl Compr Canc Netw 16(9):1041-1053, 2018. PMID: 30181416.
44. Wang L, Saci A, Szabo PM, Chasalow SD, Castillo-Martin M, Domingo-Domenech J, Siefker-Radtke AO, Sharma P, Sfakianos JP, Gong Y, Dominguez-Andres A, Oh WK, Mulholland D, Azrilevich A, Hu L, Cordon-Cardo C, Salmon H, Bhardwaj N, Zhu J, Galsky MD. EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer. Nat Commun 9(1):3503, 2018. e-Pub 2018. PMID: 30158554.
45. Mmeje CO, Benson CR, Nogueras-González GM, Jayaratna IS, Gao J, Siefker-Radtke AO, Kamat AM, Dinney CP, Navai N, Shah JB. Determining the optimal time for radical cystectomy after neoadjuvant chemotherapy. BJU Int 122(1):89-98, 2018. e-Pub 2018. PMID: 29569824.
46. Siefker-Radtke AO, Apolo AB, Bivalacqua TJ, Spiess PE, Black PC. Immunotherapy With Checkpoint Blockade in the Treatment of Urothelial Carcinoma. J Urol 199(5):1129-1142, 2018. e-Pub 2017. PMID: 29113841.
47. Özdemir BC, Siefker-Radtke AO, Campbell MT, Subudhi SK. Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature. Eur Urol Focus 4(3):442-454, 2018. e-Pub 2017. PMID: 29056275.
48. Metcalfe MJ, Ferguson JE, Li R, Xiao L, Guo CC, Czerniak BA, Siefker-Radtke AO, Pretzsch SM, Navai N, McConkey DJ, Kamat AM, Campbell M, Dinney C. Impact of High-risk Features and Effect of Neoadjuvant Chemotherapy in Urothelial Cancer Patients with Invasion into the Lamina Propria on Transurethral Resection in the Absence of Deep Muscle Invasion. Eur Urol Focus 3(6):577-583, 2017. e-Pub 2017. PMID: 28753816.
49. Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Clark PE, Downs TM, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Gurski LA. Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 15(10):1240-1267, 2017. PMID: 28982750.
50. Wang G, Huang H, Kamat AM, Siefker-Radtke AO, Dinney CP, Troncoso P, Czerniak B, Guo CC. High-grade neuroendocrine carcinoma of the urachus-report of 3 cases. Hum Pathol 67:126-133, 2017. e-Pub 2017. PMID: 28823575.
51. Fernández MI, Williams SB, Willis DL, Slack RS, Dickstein RJ, Parikh S, Chiong E, Siefker-Radtke AO, Guo CC, Czerniak BA, McConkey DJ, Shah JB, Pisters LL, Grossman HB, Dinney CP, Kamat AM. Clinical risk stratification in patients with surgically resectable micropapillary bladder cancer. BJU Int 119(5):684-691, 2017. e-Pub 2016. PMID: 27753185.
52. Fox MD, Xiao L, Zhang M, Kamat AM, Siefker-Radtke AO, Zhang L, Dinney CP, Czerniak B, Guo CC. Plasmacytoid Urothelial Carcinoma of the Urinary Bladder: A Clinicopathologic and Immunohistochemical Analysis of 49 Cases. Am J Clin Pathol 147(5):500-506, 2017. e-Pub 2017. PMID: 28371875.
53. Solomon JP, Lowenthal BM, Kader AK, Parsons JK, Flaig TW, Siefker-Radtke AO, Dyrskjøt L, Hansel DE. Challenges in the Diagnosis of Urothelial Carcinoma Variants: Can Emerging Molecular Data Complement Pathology Review?. Urology 102:7-16, 2017. e-Pub 2016. PMID: 27769917.
54. Gakis G, Schubert T, Alemozaffar M, Bellmunt J, Bochner BH, Boorjian SA, Daneshmand S, Huang WC, Kondo T, Konety BR, Laguna MP, Matin SF, Siefker-Radtke AO, Shariat SF, Stenzl A. Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of localized high-risk disease. World J Urol 35(3):327-335, 2017. e-Pub 2016. PMID: 27043218.
55. Pham MN, Apolo AB, De Santis M, Galsky MD, Leibovich BC, Pisters LL, Siefker-Radtke AO, Sonpavde G, Steinberg GD, Sternberg CN, Tagawa ST, Weizer AZ, Woods ME, Milowsky MI. Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer. World J Urol 35(3):367-378, 2017. e-Pub 2016. PMID: 27342991.
56. Sharma P, Retz M, Siefker-Radtke AO, Baron A, Necchi A, Bedke J, Plimack ER, Vaena D, Grimm MO, Bracarda S, Arranz JÁ, Pal S, Ohyama C, Saci A, Qu X, Lambert A, Krishnan S, Azrilevich A, Galsky MD. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol 18(3):312-322, 2017. e-Pub 2017. PMID: 28131785.
57. Ochoa AE, Choi W, Su X, Siefker-Radtke AO, Czerniak B, Dinney C, McConkey DJ. Specific micro-RNA expression patterns distinguish the basal and luminal subtypes of muscle-invasive bladder cancer. Oncotarget. e-Pub 2016. PMID: 27845906.
58. Dadhania V, Zhang M, Zhang L, Bondaruk J, Majewski T, Siefker-Radtke AO, Guo CC, Dinney C, Cogdell DE, Zhang S, Lee S, Lee JG, Weinstein JN, Baggerly K, McConkey D, Czerniak B. Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use. EBioMedicine 12:105-117, 2016. e-Pub 2016. PMID: 27612592.
59. Clark PE, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Kader AK, Kibel AS, Kuzel TM, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak D, Plimack ER, Pohar KS, Porter MP, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Smith C. NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. J Natl Compr Canc Netw 14(10):1213-1224, 2016. PMID: 27697976.
60. Kim C, Gao J, Shannon VR, Siefker-Radtke A. Systemic sarcoidosis first manifesting in a tattoo in the setting of immune checkpoint inhibition. BMJ Case Rep 2016, 2016. e-Pub 2016. PMID: 27797838.
61. Pal SK, Agarwal N, Boorjian SA, Hahn NM, Siefker-Radtke AO, Clark PE, Plimack ER. National Comprehensive Cancer Network Recommendations on Molecular Profiling of Advanced Bladder Cancer. J Clin Oncol 34(27):3346-8, 2016. e-Pub 2016. PMID: 27458279.
62. Siefker-Radtke AO, Zhang XQ, Guo CC, Shen Y, Pirollo KF, Sabir S, Leung C, Leong-Wu C, Ling CM, Chang EH, Millikan RE, Benedict WF. A Phase l Study of a Tumor-targeted Systemic Nanodelivery System, SGT-94, in Genitourinary Cancers. Mol Ther. e-Pub 2016. PMID: 27480598.
63. McConkey DJ, Choi W, Shen Y, Lee IL, Porten S, Matin SF, Kamat AM, Corn P, Millikan RE, Dinney C, Czerniak B, Siefker-Radtke AO. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer. Eur Urol 69(5):855-862, 2016. e-Pub 2015. PMID: 26343003.
64. Siefker-Radtke AO, Campbell MT, Munsell MF, Harris DR, Carolla RL, Pagliaro LC. Front-line treatment with gemcitabine, paclitaxel and doxorubicin for patients with unresectable or metastatic urothelial cancer and poor renal function: Final results from a phase II study. Urology 89:83-9, 2016. e-Pub 2015. PMID: 26723185.
65. Campbell MT, Siefker-Radtke AO, Gao J. The State of Immune Checkpoint Inhibition in Urothelial Carcinoma: Current Evidence and Future Areas of Exploration. Cancer J 22(2):96-100, 2016. PMID: 27111904.
66. Guo CC, Dadhania V, Zhang L, Majewski T, Bondaruk J, Sykulski M, Wronowska W, Gambin A, Wang Y, Zhang S, Fuentes-Mattei E, Kamat AM, Dinney C, Siefker-Radtke AO, Choi W, Baggerly KA, McConkey D, Weinstein J, Czerniak B. Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer. Eur Urol. e-Pub 2016. PMID: 26988609.
67. Ho PL, Willis DL, Patil J, Xiao L, Williams SB, Melquist JJ, Tart K, Parikh S, Shah JB, Delacroix SE, Navai N, Siefker-Radtke AO, Dinney CP, Pisters LL, Kamat AM. Outcome of patients with clinically node positive bladder cancer undergoing consolidative surgery after preoperative chemotherapy: The M.D. Anderson Cancer Center experience. Urol Oncol 34(2):59.e1-8, 2016. e-Pub 2015. PMID: 26421586.
68. Dhillon J, Liang Y, Kamat AM, Siefker-Radtke AO, Dinney CP, Czerniak B, Guo CC. Urachal carcinoma: a pathologic and clinical study of 46 cases. Hum Pathol 46(12):1808-14, 2015. e-Pub 2015. PMID: 26364859.
69. Campbell MT, Millikan RE, Altinmakas E, Xiao L, Wen SJ, Siefker-Radtke AO, Aparicio A, Corn PG, Tannir NM. Phase I Trial of Sunitinib and Temsirolimus in Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer 13(3):218-24, 2015. e-Pub 2014. PMID: 25465491.
70. McConkey DJ, Choi W, Ochoa A, Siefker-Radtke AO, Czerniak B, Dinney CP. Therapeutic Opportunities in the Intrinsic Subtypes of Muscle-Invasive Bladder Cancer. Hematol Oncol Clin North Am 29(2):377-394, 2015. PMID: 25836941.
71. Mmeje C, Benson C, Nogueras-Gonzalez G, Jayaratna I, Navai N, Gao J, SieferRadtke A, Kamat A, Dinney C, Shah J.. MP65-05 Determining the Optimal Timing for Radical Cystectomy After Neoadjuvant Chemotherapy. The Journal of Urology 193(4):e808-e809, 2015. e-Pub 2015.
72. Fernandez MI, Williams SB, Willis DL, Slack RS, Dickstein R, Parikh S, Siefker-Radtke AO, Guo CC, Czerniak BA, Shah JB, Pisters LL, Grossman HB, Dinney CP, Kamat AM. MP72-02 Outcome of Patients with Micropapillary Bladder Cancer Treated with Radical Cystectomy With/Without Neoadjuvant Chemotherapy. The Journal of Urology 193(4):e921, 2015. e-Pub 2015.
73. Hussain M, Daignault S, Agarwal N, Grivas PD, Siefker-Radtke AO, Puzanov I, MacVicar GR, Levine EG, Srinivas S, Twardowski P, Eisenberger MA, Quinn DI, Vaishampayan UN, Yu EY, Dawsey S, Day KC, Day ML, Al-Hawary M, Smith DC. A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma. Cancer 120(17):2684-93, 2014. e-Pub 2014. PMID: 24802654.
74. Choi W, Czerniak B, Ochoa A, Su X, Siefker-Radtke AO, Dinney C, McConkey DJ. Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. Nat Rev Urol 11(7):400-410, 2014. e-Pub 2014. PMID: 24960601.
75. Porten S, Siefker-Radtke AO, Xiao L, Margulis V, Kamat AM, Wood CG, Jonasch E, Dinney CP, Matin SF. Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. Cancer 120(12):1794-9, 2014. e-Pub 2014. PMID: 24633966.
76. Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, Roth B, Cheng T, Tran M, Lee IL, Melquist J, Bondaruk J, Majewski T, Zhang S, Pretzsch S, Baggerly K, Siefker-Radtke AO, Czerniak B, Dinney CP, McConkey DJ. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25(2):152-65, 2014. PMID: 24525232.
77. Culp SH, Dickstein RJ, Grossman HB, Pretzsch SM, Porten S, Daneshmand S, Cai J, Groshen S, Siefker-Radtke AO, Millikan RE, Czerniak B, Navai N, Wszolek MF, Kamat AM, Dinney CP. Refining Patient Selection for Neoadjuvant Chemotherapy Prior to Radical Cystectomy. J Urol 191(1):40-7, 2014. e-Pub 2013. PMID: 23911605.
78. Solomon DA, Kim JS, Bondaruk J, Shariat SF, Wang ZF, Elkahloun AG, Ozawa T, Gerard J, Zhuang D, Zhang S, Navai N, Siefker-Radtke AO, Phillips JJ, Robinson BD, Rubin MA, Volkmer B, Hautmann R, Küfer R, Hogendoorn PC, Netto G, Theodorescu D, James CD, Czerniak B, Miettinen M, Waldman T. Frequent truncating mutations of STAG2 in bladder cancer. Nat Genet 45(12):1428-30, 2013. e-Pub 2013. PMID: 24121789.
79. Lynch SP, Shen Y, Kamat A, Grossman HB, Shah JB, Millikan RE, Dinney CP, Siefker-Radtke A. Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic down-staging and long-term outcomes. Results from a retrospective study at the M.D. Anderson Cancer Center. Eur Urol 64(2):307-13, 2013. e-Pub 2012. PMID: 22564397.
80. Galsky MD, Hendricks R, Svatek R, Bangs R, Hoffman-Censits J, Clement J, Dreicer R, Guancial E, Hahn N, Lerner SP, O'Donnell PH, Quale DZ, Siefker-Radtke AO, Shipley W, Sonpavde G, Vaena D, Vinson J, Rosenberg J. Critical analysis of contemporary clinical research in muscle-invasive and metastatic urothelial cancer: A report from the Bladder Cancer Advocacy Network Clinical Trials Working Group. Cancer 119(11):1994-8, 2013. e-Pub 2013. PMID: 23456777.
81. Dayyani F, Czerniak BA, Sircar K, Munsell MF, Millikan RE, Dinney CP, Siefker-Radtke AO. Plasmacytoid Urothelial Carcinomas - A Chemo-sensitive Cancer with Poor Prognosis, and Peritoneal Carcinomatosis. J Urol 189(5):1659 - 1661, 2013. e-Pub 2012. PMID: 23159581.
82. Siefker-Radtke AO, Dinney CP, Shen Y, Williams DL, Kamat AM, Grossman HB, Millikan RE. A Phase 2 Clinical Trial of Sequential Neoadjuvant Chemotherapy With Ifosfamide, Doxorubicin, and Gemcitabine Followed by Cisplatin, Gemcitabine, and Ifosfamide in Locally Advanced Urothelial Cancer. Cancer 119(3):540-7, 2013. e-Pub 2012. PMID: 22914978.
83. Tran MN, Choi W, Wszolek MF, Navai N, Lee IL, Nitti G, Wen S, Flores ER, Siefker-Radtke AO, Czerniak B, Dinney C, Barton M, McConkey DJ. The p63 isoform ΔNp63α inhibits epithelial-mesenchymal transition in human bladder cancer cells: Role of miR205. J Biol Chem 288(5):3275-3288, 2013. e-Pub 2012. PMID: 23239884.
84. Sternberg CN, Bellmunt J, Sonpavde G, Siefker-Radtke AO, Stadler WM, Bajorin DF, Dreicer R, George DJ, Milowsky MI, Theodorescu D, Vaughn DJ, Galsky MD, Soloway MS, Quinn DI, International Consultation on Urologic Disease-European Association of Urology Consultation on Bladder Cancer 2012. ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for Urothelial Carcinoma-Neoadjuvant and Adjuvant Settings. Eur Urol 63(1):58-66, 2013. e-Pub 2012. PMID: 22917984.
85. Qi W, White MC, Choi W, Guo C, Dinney C, McConkey DJ, Siefker-Radtke A. Inhibition of inducible heat shock protein-70 (hsp72) enhances bortezomib-induced cell death in human bladder cancer cells. PLoS One 8(7):e69509, 2013. e-Pub 2013. PMID: 23874968.
86. Rodney AJ, Tannir NM, Siefker-Radtke AO, Liu P, Walsh GL, Millikan RE, Swisher SG, Tu SM, Pagliaro LC. Survival outcomes for men with mediastinal germ-cell tumors: The University of Texas MD Anderson Cancer Center experience. Urol Oncol 30(6):879-85, 2012. e-Pub 2010. PMID: 20933444.
87. Marquis L, Tran M, Choi W, Lee IL, Huszar D, Siefker-Radtke AO, Dinney C, McConkey DJ. p63 expression correlates with sensitivity to the Eg5 inhibitor ZD4877 in bladder cancer cells. Cancer Biol Ther 13(7):477- 486, 2012. e-Pub 2012. PMID: 22361733.
88. Alva AS, Matin SF, Lerner SP, Siefker-Radtke AO. Perioperative chemotherapy for upper tract urothelial cancer. Nat Rev Urol 9(5):266 - 273, 2012. e-Pub 2012. PMID: 22487872.
89. Choi W, Shah JB, Tran M, Svatek R, Marquis L, Lee IL, Yu D, Adam L, Wen S, Shen Y, Dinney C, McConkey DJ, Siefker-Radtke A. p63 expression defines a lethal subset of muscle-invasive bladder cancers. PLoS One 7(1):e30206, 2012. e-Pub 2012. PMID: 22253920.
90. Rajput MZ, Kamat AM, Clavell-Hernandez J, Siefker-Radtke AO, Grossman HB, Dinney CP, Matin SF. Perioperative outcomes of laparoscopic radical nephroureterectomy and regional lymphadenectomy in patients with upper urinary tract urothelial carcinoma after neoadjuvant chemotherapy. Urology 78(1):61-7, 2011. e-Pub 2011. PMID: 21354598.
91. Black PC, Dinney CP, Brown GA, Kassouf W, Siefker-Radtke AO, Munsell MF, Grossman HB, Kamat AM. The role of radical cystectomy in patients with clinical T4b bladder cancer. Urol Oncol 29(2):157-161, 2011. e-Pub 2010. PMID: 20456984.
92. Svatek RS, Shariat SF, Lasky RE, Skinner EC, Novara G, Lerner SP, Fradet Y, Bastian PJ, Kassouf W, Karakiewicz PI, Fritsche HM, Müller SC, Izawa JI, Ficarra V, Sagalowsky AI, Schoenberg MP, Siefker-Radtke AO, Millikan RE, Dinney CP. The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. Clin Cancer Res 16(17):4461-7, 2010. e-Pub 2010. PMID: 20651056.
93. Matin SF, Margulis V, Kamat A, Wood CG, Grossman HB, Brown GA, Dinney CP, Millikan R, Siefker-Radtke AO. Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. Cancer 116(13):3127-34, 2010. PMID: 20564621.
94. Siefker-Radtke A. Bladder cancer: can we move beyond chemotherapy?. Curr Oncol Rep 12(4):278-83, 2010. PMID: 20446067.
95. McConkey DJ, Lee S, Choi W, Tran M, Majewski T, Lee S, Siefker-Radtke AO, Dinney C, Czerniak B. Molecular genetics of bladder cancer: Emerging mechanisms. Urol Oncol 28(4):429-40, 2010. PMID: 20610280.
96. Childs MA, Wood CG, Spiess, PE, Debiane L, Hernandez M, Matin S, Millikan R, Siefker-Radtke AO, Scott SM, Pisters LL. Early results of chemotherapy with retroperitoneal lymph node dissection for isolated retroperitoneal recurrence of upper urinary tract urothelial carcinoma after nephroureterectomy. The Canadian Journal of Urology 17(3):5184-5189, 2010.
97. Logothetis CJ, Siefker-Radtke A. Words of wisdom. Re: final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium. Eur Urol 57(4):728-9, 2010. PMID: 20965043.
98. Hussain MH, Wood DP, Bajorin DF, Bochner BH, Dreicer R, Lamm DL, O'Donnell MA, Siefker-Radtke AO, Theodorescu D, Dinney CP. Bladder cancer: narrowing the gap between evidence and practice. J Clin Oncol 27(34):5680-4, 2009. e-Pub 2009. PMID: 19858384.
99. McConkey DJ, Choi W, Marquis L, Martin F, Williams MB, Shah J, Svatek R, Das A, Adam L, Kamat A, Siefker-Radtke AO, Dinney C. Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer Metastasis Rev 28(3-4):335-44, 2009. PMID: 20012924.
100. Svatek RS, Siefker-Radtke AO, Dinney CP. Management of metastatic urothelial cancer: the role of surgery as an adjunct to chemotherapy. Can Urol Assoc J 3(6 Suppl 4):S228-31, 2009. PMID: 20019991.
101. Adam L, Zhong M, Choi W, Qi W, Nicoloso M, Arora A, Calin G, Wang H, Siefker-Radtke AO, McConkey D, Bar-Eli M, Dinney C. miR-200 expression regulates epithelial to mesenchymal transition in bladder cancer cells and reverses resistance to EGFR therapy. Clin Cancer Res 15(16):5060-72, 2009. e-Pub 2009. PMID: 19671845.
102. Siefker-Radtke AO, Kamat AM, Grossman HB, Williams DL, Qiao W, Thall PF, Dinney CP, Millikan RE. Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer. J Clin Oncol 27(16):2592-7, 2009. e-Pub 2009. PMID: 19414678.
103. Kassouf W, Agarwal PK, Grossman HB, Leibovici D, Munsell MF, Siefker-Radtke AO, Pisters LL, Swanson DA, Dinney CP, Kamat AM. Outcome of patients with bladder cancer with pN+ disease after preoperative chemotherapy and radical cystectomy. Urology 73(1):147-52, 2009. e-Pub 2008. PMID: 18848348.
104. Tannir NM, Thall PF, Ng CS, Wang X, Wooten L, Siefker-Radtke AO, Mathew P, Pagliaro L, Wood C, Jonasch E. A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents. J Urol 180(3):867-72; discussion 872, 2008. e-Pub 2008. PMID: 18635226.
105. Black PC, Brown GA, Inamoto T, Shrader M, Arora A, Siefker-Radtke AO, Adam L, Theodorescu D, Wu X, Munsell MF, Bar-Eli M, McConkey DJ, Dinney CP. Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. Clin Cancer Res 14(5):1478-86, 2008. PMID: 18316572.
106. Siefker-Radtke AO. Metastatic squamous cell carcinoma of the urachus: review. Clinical Advances in Hematology & Oncology 5(11):887-90, 2007.
107. Kassouf W, Spiess PE, Brown GA, Munsell MF, Grossman HB, Siefker-Radtke AO, Dinney CP, Kamat AM. P0 stage at radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors. Eur Urol 52(3):769-74, 2007. e-Pub 2007. PMID: 17434254.
108. Kassouf W, Spiess PE, Siefker-Radtke AO, Swanson D, Grossman HB, Kamat AM, Munsell MF, Guo CC, Czerniak BA, Dinney CP. Outcome and patterns of recurrence of nonbilharzial pure squamous cell carcinoma of the bladder: a contemporary review of The University of Texas M. D. Anderson Cancer Center experience. Cancer 110(4):764-9, 2007. PMID: 17614317.
109. Kamat AM, Dinney CP, Gee JR, Grossman HB, Siefker-Radtke AO, Tamboli P, Detry MA, Robinson TL, Pisters LL. Micropapillary bladder cancer: a review of The University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients. Cancer 110(1):62-7, 2007. PMID: 17542024.
110. Siefker-Radtke A. Urachal carcinoma: surgical and chemotherapeutic options. Expert Rev Anticancer Ther 6(12):1715-21, 2006. PMID: 17181485.
111. Tannir NM, Cohen L, Wang X, Thall P, Mathew PF, Jonasch E, Siefker-Radtke AO, Pagliaro LC, Ng CS, Logothetis C. Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma. Cancer 107(9):2254-61, 2006. PMID: 17029276.
112. Tannir N, Jonasch E, Pagliaro LC, Mathew P, Siefker-Radtke AO, Rhines L, Lin P, Tibbs R, Do KA, Lin SH, Tu SM. Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma. Cancer 107(3):497-505, 2006. PMID: 16795067.
113. Kassouf W, Swanson D, Kamat AM, Leibovici D, Siefker-Radtke AO, Munsell MF, Grossman HB, Dinney CP. Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson cancer center experience. J Urol 175(6):2058-62, 2006. PMID: 16697803.
114. Siefker-Radtke A. Systemic chemotherapy options for metastatic bladder cancer. Expert Rev Anticancer Ther 6(6):877-85, 2006. PMID: 16761931.
115. Abrahams NA, Moran C, Reyes AO, Siefker-Radtke AO, Ayala AG. Small cell carcinoma of the bladder: a contemporary clinicopathological study of 51 cases. Histopathology 46(1):57-63, 2005. PMID: 15656887.
116. Dinney CP, McConkey DJ, Millikan RE, Wu X, Bar-Eli M, Adam L, Kamat AM, Siefker-Radtke AO, Tuziak T, Sabichi AL, Grossman HB, Benedict WF, Czerniak B. Focus on bladder cancer. Cancer Cell 6(2):111-6, 2004. PMID: 15324694.
117. Siefker-Radtke AO, Dinney CP, Abrahams NA, Moran C, Shen Y, Pisters LL, Grossman HB, Swanson DA, Millikan RE. Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience. J Urol 172(2):481-4, 2004. PMID: 15247709.
118. Siefker-Radtke AO, Walsh GL, Pisters LL, Shen Y, Swanson DA, Logothetis CJ, Millikan RE. Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience. J Urol 171(1):145-8, 2004. PMID: 14665863.
119. Millikan R, Siefker-Radtke AO, Grossman HB. Neoadjuvant chemotherapy for bladder cancer. Urol Oncol 21(6):464-7, 2003. PMID: 14693274.
120. Sweeney P, Millikan R, Donat M, Wood C, Siefker Radtke AO, Pettway C, Grossman HB, Dinney C, Swanson D, Pisters L. Is there a role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder?. J Urol 169(6):2113-7, 2003. PMID: 12771730.
121. Siefker-Radtke AO, Gee J, Shen Y, Wen S, Daliani D, Millikan RE, Pisters LL. Multimodality management of urachal carcinoma: the M. D. Anderson Cancer Center experience. J Urol 169(4):1295-8, 2003. PMID: 12629346.
122. Siefker-Radtke AO, Millikan RE, Tu SM, Moore DF, Smith TL, Williams D, Logothetis CJ. Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer. J Clin Oncol 20(5):1361-7, 2002. PMID: 11870180.
123. Hsi LC, Tsai AL, Kulmacz RJ, English DG, Siefker AO, Otto JC, Smith WL. Trp387 and the putative leucine zippers of PGH synthases-1 and -2. J Lipid Mediators 6(1-3):131-138, 1993. PMID: 8357979.

Invited Articles

1. Siefker-Radtke AO, Curti B. Immunotherapy in Metastatic Urothelial Carcinoma: Focus on Immune Checkpoint Inhibition. Nat Rev Urol 15(2):1-14, 2018. e-Pub 2017. PMID: 29205200.
2. Campbell MT, Shah AY, Matin SF, Siefker-Radtke AO. Optimizing management of upper tract urothelial carcinoma. Urol Oncol 35(7):492-498, 2017. e-Pub 2017. PMID: 28579283.
3. Siefker-Radtke A. Urachal Adenocarcinoma: A Clinician's Guide for Treatment. Semin Oncol 39(5):619-624, 2012. PMID: 23040259.

Manuals, Teaching Aids, Other Teaching Publications

1. Siefker-Radtke AO. NCCN Bladder Cancer, 2016.
2. Siefker-Radtke AO. NCCN Penile Cancer, 2016.
3. Siefker-Radtke AO, Kamat A. Bladder Cancer Practice Guidelines, 2006.
4. Edward H. Lin, MD, Richard Lozano, RPh, Daniel DKarp, MD. Color-Matrix Cancer Staging and Treatment Handbook, 2005.

Other Articles

1. Siefker-Radtke AO, Campbell MT Reply to B. Biswas et al. J Clin Oncol 35(18):2097, 2017. PMID: 28471712.
2. Siefker AO, Campbell MT Reply to B. Biswas et al. J Clin Oncol 35(18):2097, 2017. PMID: 28471712.

Editorials

1. Andreev-Drakhlin A, Gao J, Siefker-Radtke AO. Levelling the Evidence: A Comparison of Neoadjuvant and Adjuvant Treatment for Upper Tract Urothelial Carcinoma. European Urology, 2020.
2. Shah AY, Gao J, Siefker-Radtke AO. Five new therapies or just one new treatment? A critical look at immune checkpoint inhibition in urothelial cancer. Immunotherapy 9(10):781-784, 2017. PMID: 28877627.
3. Siefker-Radtke AO, Campbell MT. Now is the time for perioperative chemotherapy in upper tract urothelial cancer. J Clin Oncol 35(8):816-817, 2017. PMID: 28165904.
4. Siefker-Radtke A. Editorial Comment. J Urol 195(6):1696, 2016. PMID: 26970453.
5. Siefker-Radtke AO, Gao J. Towards effective adjuvant treatment for urothelial cancer. Lancet Oncol 16(1):9-10, 2015. PMID: 25498220.
6. Siefker-Radtke A. Dose-dense makes sense: Emerging concepts in urothelial cancer. Genitourinary Cancers Symposium Daily News(1):18, Feb 18, 2011, 2011.
7. Logothetis CJ, Siefker-Radtke A. Re: Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium. Eur Urol 57(4):728-9, 2010.
8. Siefker-Radtke AO. Surgical consolidation of initially unresectable urothelial carcinoma: an incremental opportunity to cure. Expert Rev Anticancer Ther 9(12):1701-3, 2009. PMID: 19954279.

Abstracts

1. Siefker-Radtke AO. Management of fibroblast growth factor receptor inhibitor (FGFRi) treatment-emergent adverse events (TEAEs) of interest in patients (Pts) with locally advanced or metastatic urothelial carcinoma (mUC). 2021 GU ASCO, 2021.
2. Moreno V, Loriot Y, Valderrama B, Beato C, Vano Y, Fleming M, Duran I, Siena S, Tolbert J, OHagan A, Akapame S, Lau Y, Geoffrois L, Tagawa S, Mellado B, Siefker-Radtke AO. Does escalation results from phase Ib/II Norse study of erdafitinib (ERDA) + PD-1 inhibitor JNJ-63723283 (Cetrelimab [CET]) in patients (pts) with metastatic or locally advanced urothelial carcinoma (mUC) and selected fibroblast growth factor receptor (FGFR) gene alterations. J Clin Oncol, 2020.
3. Siefker-Radtke AO, Steinberg G, Bedke J, Nishiyama H, Fang X, Kataria R, Moreno B, Hoimes C. Phase III study of perioperative pembrolizumab (pembro) plus neoadjuvant chemotherapy (chemo) versus placebo plus neoadjuvant chemo in cisplatin-eligible patients (pts) with muscle-invasive bladder cancer (MIBC): KEYNOTE-866. 2020 Genitourinary Cancers Symposium, 2020.
4. Chaudhry A, Sternberg C, De Santis M, Bellmunt J, Necchi A, Powles T, Cantero F, Marszewska M, Grzyb M, McSheehy P, Braun S, Siefker-Radtke AO. FIDES-02, a phase Ib/II study of derazantinib (DZB) as monotherapy and combination therapy with atezolizumab (A) in patients with surgically unresectable or metastaticurothelial cancer (UC) and FGFR genetic aberrations. J Clin Oncol, 2020.
5. Loriot Y, Balar A, De Wit R, Garcia J, Grivas P, Matsubara N, Moreno B, Sbar E, Jia X, Dutcus C, Siefker-Radtke AO, Roussy G. Phase III study of first-line pembrolizumab (pembro) plus lenvatinib (len) in patients (pts) with advanced urothelial carcinoma (UC) ineligible for platinum-based chemotherapy: LEAP-011. J Clin Oncol, 2020.
6. Huddart R, Siefker-Radtke AO, Balar A, Bilen M, Powles T, Bamias A, Castellano D, Khalil M, Van Der Heijden M, Koshkin V, Pook D, Ozguroglu M, Santiago L, Saab R, Li P, Tagliaferri MC, Lin W, Tagliaferri M, Loriot Y. PIVOT-10: A phase II study of bempegaldesleukin (NKTR-214) in combination with nivolumab (NIVO) in cisplatin (cis) ineligible patients with previously untreated locally advanced or metastatic urothelial cancer (mUC). J Clin Oncol, 2020.
7. Siefker-Radtke AO, Steinberg G, Bedke J, Nishiyama H, Martin J, Kataria R, Frenkl TL, Hoimes CJ. Phase III study of perioperative pembrolizumab (pembro) or placebo (pbo) in combination with neoadjuvant chemotherapy in cisplatin (cis)-eligible patients (pts) with muscle-invasive bladder cancer. 2019 ESMO Congress, 2019.
8. Matulay JT, Campbell MT, Narayan VM, Seif MA, Lim AH, Shah AY, Msaouel P, Gao J, Siefker-Radtke AO, Dinney CPN, Kamat AM, Navai N. Pathologic outcomes after neoadjuvant chemotherapy for high-risk muscle invasive bladder cancer. 2019 ESMO Congress, 2019.
9. Siefker-Radtke AO, Zhong B, Qi K, Shalaby W, De Porre P, O’Hagan A, Mahadevia P, Loriot Y. Analysis of response to prior therapies and therapies after treatment with erdafitinib in fibroblast growth factor receptor (FGFR)-positive patients (pts) with metastatic urothelial carcinoma (mUC). 2019 ESMO Congress, 2019.
10. S Tagawa, A Siefker-Radtke, A -G Dosne, B Zhong, K Qi, W Shalaby, A O’Hagan, P De Porre, P Mahadevia, Y Loriot. Hyperphosphatemia due to erdafitinib (a pan-FGFR Inhibitor) and anti-tumour activity among patients (Pts) with advanced urothelial carcinoma (UC). 2019 ESMO Congress, 2019.
11. Loriot Y, Balar A, de Wit R, Garcia JA, Grivas P, Matsubara N, Frenkl TL, Sbar E, Jia XC, Fouad T, Siefker-Radtke AO. Phase III LEAP-011 trial: First-line pembrolizumab with lenvatinib in patients with advanced urothelial carcinoma ineligible to receive platinum-based chemotherapy. 2019 ESMO Congress, 2019.
12. Siefker-Radtke AO, Lugowska I, Tupikowski K, Andric ZG, Rezazadeh Kalebasty A, Curigliano G, Vaena D, Vogl FD, Currie G, Abella S, Kelly W. Clinical activity of vofatamab (V), an FGFR3 selective antibody in combination with pembrolizumab (P) in metastatic urothelial carcinoma (mUC), updated interim analysis of FIERCE-22. 2019 ESMO Congress, 2019.
13. Loriot Y, Van Sanden S, Diels J, Rahhali N, Seshagiri D, Kowalski B, Fleming S, De Porre P, Siefker-Radtke AO. Erdafitinib (erda) versus available therapies in advanced urothelial cancer: A matching adjusted indirect comparison. 2019 ESMO Congress. e-Pub 2019.
14. Choi W, McConkey D, Lee ID, Currie G, Abella E, Kelly W, Siefker-Radtke AO. Gene Expression Profiling in Wildtype and Mutant FGFR3 Metastatic Urothelial Cancer Treated With Combination Therapy With Vofatamab and Pembrolizumab. 2019 Bladder AACR, 2019.
15. Siefker-Radtke AO, Balar A, Fishman MN, Giovanni G, Gao J, Diab A, Bilen MA. NKTR-214 + nivolumab in first-line advanced/metastatic urothelial carcinoma (mUC): Updated results from PIVOT-02. 2019 GU ASCO, 2019.
16. Siefker-Radtke AO, Loriot Y, Moy C, Cherkas Y, Motley C, Avadhani A, O'Hagan A, De Porre P, Lorenzi M, Mccaffery I. Erda ctDNA. 2019 GU ASCO, 2019.
17. Msaouel P, Slack-Tidwell R, Genovese G, Daw N, Siefker-Radtke AO, Tannir N. Phase II trial of ixazomib combined with gemcitabine and doxorubicin in patients with SMARCB1-deficient kidney malignancies. J Clin Oncol, 2019.
18. Choi S, Campbell M, Shah A, Navai N, Kamat A, Dinney C, Nguyen Q, Siefker-Radtke AO. Prophylactic cranial irradiation (PCI) significantly decreases risk of brain metastases in patients with bulky, higher stage small-cell urothelial cancer. 2019 Genitourinary Cancers Symposium, 2019.
19. Santiago-Walker A, Chen F, Loriot Y, Siefker-Radtke AO, Sun L, Sundaram R, De Porre P, Patel K, Wan Y. Predictive value of fibroblast growth factor receptor (FGFR) mutations and gene fusions on anti-PD-(L)1 treatment outcomes in patients (pts) with advanced urothelial cancer (UC). J Clin Oncol, 2019.
20. Alhalabi O, Campbell M, Slack-Tidwell R, Siefker-Radtke AO, Shah A, Efstathiou E, Wang W, Titus M, Czerniak B, Zhang M, Guo C, Logothetis C, Gao J. A phase II trial to evaluate pemetrexed clinical responses in relation to tumor methylthioadenosine phosphorylase (MTAP) gene status in patients with previously treated metastatic urothelial carcinoma. J Clin Oncol, 2019.
21. Santiago-Walker A, Moy C, Cherkas Y, Loriot Y, Siefker-Radtke AO, Motley C, Avadhani A, OHagan A, De Porre P, Lorenzi M, McCaffery I. Analysis of FGFR alterations from circulating tumor DNA (ctDNA) and Tissue in a phase II trial of erdafitinib in urothelial carcinoma (UC). J Clin Oncol, 2019.
22. Rosenberg JE, Sharma P, de Braud FGM, Basso U, Calvo E, Bono P, Morse M, Ascierto PA, Lopez-Martin JA, Brossart P, Rohrberg KS, Reguart N, Lin WH, Meadows-Shropshire S, Saci A, Callahan M, Siefker-Radtke AO. Nivolumab (N) Alone or in Combination With Ipilimumab (I) in Patients (pts) With Platinum Pretreated Metastatic Urothelial Carcinoma (mUC). ESMO 2018 Congress, 2018.
23. Sharma P, Baron A, Necchi A, Plimack ER, Pal SK, Bedke J, Arranz JA, Vaena D, Grimm M, Bracarda S, Retz M, Siefker-Radtke AO, Ohyama C, Grossfeld G, Lu H, Saci A, Tang H, Galsky MD. Abstract CT178: Nivolumab monotherapy in patients with advanced platinum-resistant urothelial carcinoma: Efficacy and safety update and association between biomarkers and overall survival in CheckMate 275. AACR Annual Meeting 78(13), 2018.
24. Diab A, Hurwitz ME, Cho DC, Papadimitrakopoulou V, Curti BD, Tykodi SS, Puzanov I, Ibrahim NK, Tolaney SM, Tripathy D, Gao J, Siefker-Radtke AO, Clemens W, Tagliaferri MA, Gettinger SN, Kluger HM, Larkin JMG, Grignani G, Sznol M, Tannir NM. NKTR-214 (CD122-biased agonist) plus nivolumab in patients with advanced solid tumors: Preliminary phase 1/2 results of PIVOT. ASCO 2018 Annual Meeting, 2018.
25. Siefker-Radtke AO, Necchi A, Park SH, Garcia-Donas J, Huddart RA, Burgess EF, Fleming MT, Rezazadeh A, Mellado B, Varlamov S, Joshi M, Duran I, Tagawa ST, O'Hagan A, Avadhani AN, Zhong B, De Porre P, Loriot Y. First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFR alt). J Clin Oncol 36(suppl; abstr 4503), 2018. e-Pub 2018.
26. Gao J, Siefker-Radtke AO, Navai N, Campbell MT, Slack R, Guo C, Kamat AM, Matin SF, Papadopoulos JN, Araujo JC, Shah AY, Blando JM, Vence LM, Duan F, Basu S, Singh S, Zhao H, Dinney C, Sharma P. A pilot pre-surgical study evaluating anti-PD-L1 durvalumab (durva) plus anti-CTLA-4 tremelimumab (treme) in patients with muscle-Invasive, high-risk urothelial bladder carcinoma who are ineligible for cisplatin-based neoadjuvant chemotherapy. J Clin Oncol, 2018.
27. Loriot Y, Necchi A, Park SH, Garcia-Donas, Huddart R, Burgess E, Fleming M, Rezazadeh A, Mellado B, Varlamov S, Joshi M, Duran I, O'Hagan A, Avadhani A, Zhong B, Stuyckens K, Dosne AG, Siefker-Radtke AO. Erdafitinib (ERDA; JNJ-42756493), a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR2 and FGFR3 alterations (FGFR+): phase 2 continuous (cont) vs intermittent (int) dosing. 2018 Genitourinary Cancers Symposium, 2018.
28. Siefker-Radtke AO, Necchi A, Rosenbaum E, Culine S, Burgess EF, O'Donnell PH, Tagawa ST, Zakharia Y, Loriot Y. Efficacy of programmed death 1 (PD-1) and programmed death 1 ligand (PD-L1) inhibitors in patients with FGFR alterations: results from a data analysis of an ongoing Phase 2 study of erdafitinib (JNJ-42756493) in patients (pts) with advanced urothelial cancer (UC). 2018 Genitourinary Cancers Symposium, 2018.
29. Galsky MD, Saci A, Szabo PM, Wang L, Zhu J, Azrilevich A, Fischer BS, Necchi A, Siefker-Radtke AO, Sharma P. Fibroblast growth factor receptor 3 (FGFR3), peroxisome proliferator-activated receptor gamma (PPARg), and outcomes with nivolumab (nivo) in metastatic urothelial cancer (UC). 2018 Genitourinary Cancers Symposium, 2018.
30. Siefker-Radtke AO, Necchi A, Rosenbaum E, Culine S, Burgess EF, O'Donnell PH, Tagawa ST, Zakharia Y, O'Hagan A, Avadhani AN, Zhong B, Santiago-Walker AE, Roccia T, Loriot Y. Efficacy of programmed death 1 (PD-1) and programmed death 1 ligand (PD-L1) inhibitors in patients with FGFR mutations and gene fusions: Results from a data analysis of an ongoing phase 2 study of erdafitinib (JNJ-42756493) in patients with advanced urothelial cancer (UC). Journal of Clinical Oncology 36(suppl;65 abstr 450), 2018.
31. Santiago-Walker A, Moy C, Cherkas Y, Loriot Y, Siefker-Radtke AO, Motley C, Avadhani A, O'Hagan A, De Porre P, Lorenzi MV, McCaffery I. Analysis of FGFR alterations from circulating tumor DNA (ctDNA) and Tissue in a phase II trial of erdafitinib in urothelial carcinoma (UC). 2018 GU ASCO, 2018.
32. Santiago-Walker A, Chen F, Loriot Y, Siefker-Radtke AO, Sun L, Sundaram R, De Porre P, Patel K, Wan Y. Predictive value of fibroblast growth factor receptor (FGFR) mutations and gene fusions on anti-PD-(L)1 treatment outcomes in patients (pts) with advanced urothelial cancer (UC). 2018 GU ASCO, 2018.
33. Bedke J, Sharma P, Retz M, Siefker-Radtke AO, Necchi A, Plimack ER, Vaena D, Grimm MO, Bracarda S, Arranz JA, Pal S, Ohyama C, Gruellich C, Von Amsverg G, Steiner T, Saci A, Lambert A, Azrilevich A, Galsky MD. Efficacy Update of Nivolumab Monotherapy in Patients With Metastatic or Surgically Unresectable Locally Advanced Urothelial Carcinoma Who Have Received Prior Treatment: Phase II Checkmate 275 Study. Annual Meeting of Germans, Austrian and Swiss companies for Hematology and Medical Oncology, German Society of Hematology and Oncology (DGHO), 2017.
34. Galsky MD, Saci A, Szabo PM, Azrilevich A, Horak C, Lambert A, Siefker-Radtke AO, Necchi A, Sharma P. Impact of tumor mutation burden on nivolumab efficacy in second-line urothelial carcinoma patients: exploratory analysis of the phase II checkmate. ESMO 2017 Congress, An Oncol 28(5), 2017.
35. Choi W, Sundi D, Metcalfe M, Lee I, Pretzsch S, Bondaruk J, Plimack E, Siefker-Radtke AO, Czerniak B, Dinney C, McConkey. Impact of molecular subtypes on predicting chemotherapy response and survival in muscle invasive bladder cancer. 2017 American Association for Cancer Research Meeting 77(13), 2017.
36. Siefker-Radtke AO, Mellado B, Decaestecker K, Burke JM, O'Hagan A, Avadhani A, Zhong B, Santiago-Walker A, Brookman-May S, De Porre P, Garcia-Donas J. Ongoing phase 2 study of erdafitinib (JNJ-42756493), a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients (pts) with metastatic or unresectable urothelial carcinoma (M/UR UC) and FGFR gene alterations. 2016 ESMO Congress, 2016.
37. Siefker-Radtke AO, Mellado B, Decaesteck K, Burke JM, O'Hagan A, Avadhani AN, Zhong B, Santiago-Walker AE, De Porre P, Brookman-May S, Garcia-Donas J. A phase 2 study of JNJ-42756493, a pan-FGFR tyrosine kinase inhibitor, in patients (pts) with metastatic or unresectable urothelial cancer (UC) harboring FGFR gene alterations. 2016 ASCO Annual Meeting, 2016.
38. Kamat AM, Bellmunt J, Choueiri TK, Nam K, DeSantis M, Dreicer R, Hahn NM, Perini RF, Siefker-Radtke AO, Sonpavde G, DeWit R, Witjes A, Keefe SM, Bajorin DF. KEYNOTE-057: Phase 2 study of pembrolizumab for patients (pts) with Bacillus Calmette Guerin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (NMIBC). 2016 ASCO Annual Meeting, 2016.
39. Benson C, Navai N, Gao J, Siefker-Radtke AO, Nogueras Gonzalez G, Golla V, Alliston J, Kamat A, Dinney C, Shah J. MP49-12 Neoadjuvant chemotherapy for invasive bladder cancer: Is it right for everyone?. 2016 American Urological Association Meeting, 2016.
40. Siefker-Radtke AO, Zhang X, Guo CC, Pirollo KF, Chang EH, Millikan RE, Benedict W. Systemic administration using targeted gene delivery with SGT-RB94 shows evidence of tumor targeting and anticancer activity: a phase I first-in-man trial. 2016 American Association for Cancer Research Meeting, 2016.
41. Campbell MT, McConkey D, Matin SF, Kamat AM, Dinney C, Wang J, Gao J, Siefker-Radtke AO. The hotspot mutational landscape of upper tract and bladder urothelial cancers and correlation to survival. 2016 GU ASCO Meeting, 2016.
42. Mmeje CQ, Slade A, Slack R, Navai N, Gao J, Siefker-Radtke AO, Kamat AM, Dinney C, Shah J. The utility of neutrophil-to-lymphocyte ratio in determining survival outcomes in patients treated with neoadjuvant chemotherapy and radical cystectomy for high-risk bladder cancer. 2016 GU ASCO Meeting, 2016.
43. Siefker-Radtke AO. Current Challenges in Managing Bladder Cancer. 2015 Society of Urologic Oncology Meeting, 2015.
44. Corn, PG, Tu SM, Zurita AJ, Subudhi SK, Araujo JC, Kim J, Jonasch E, Pagliaro LC, Siefker-Radtke AO, Wang J, Wang X, Heath EI, Logothetis C, Aparicio A. A multi-institutional randomized phase II study (NCT01505868) of cabazitaxel (CAB) plus or minus carboplatin (CARB) in men with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 33(suppl; abstr 5010), 2015.
45. Bajorin DF, Plimack ER, Siefker-Radtke AO, Choueiri TK, DeWit R, Sonpavde G, Gipson A, Brown H, Mai Y, Pang L, Perini RF, Bellmut J. Phase 2 study of pembrolizumab (MK-3475) as first-line therapy for patients (pts) with unresectable or metastatic urothelial cancer ineligible for cisplatin-based therapy. J Clin Oncol 33(suppl; abstr TPS4572), 2015.
46. Siefker-Radtke AO, Choi W, Proten S, Shen Y, Kamat AM, Matin SF, Millikan RE, Dinney C, Czerniak B, McConkey DJ. The basal subtype to predict clinical benefit from neoadjuvant chemotherapy: Final results from a phase II clinical trial of DDMVAC + bevacizumab. J Clin Oncol 33(suppl; abstr 4531), 2015.
47. Bellmunt J, Sonpavde G, DeWit R, Choueiri TK, Siefker-Radtke AO, Plimack ER, Lewis NM, Brown H, Mai Y, Gause CK, Kaufman DR, Bajorin DF,. Randomized phase 3 trial of pembrolizumab (MK-3475) versus paclitaxel, docetaxel, or vinflunine for previously treated metastatic urothelial cancer. J Clin Oncol 33(suppl; abstr TPS4571), 2015.
48. Mmeje, CH, Benson, C, Nogueras-Gonzalez GM, Jayaratna IS, Navai N, Gao J, Siefker-Radtke AO, Kamat AM, Dinney CP, Shah JB. Determining the optimal timing for radical cystectomy after neoadjuvant chemotherapy. American Urological 2015 Annual Meeting, 2015.
49. Fernandez M, Williams SB, Willis D, Slack R, Dickstein R, Parikh S, Siefker-Radtlke AO, Guo CC, Czernial BA, Shah JB, Pisters LL, Grossman HB, Dinney CP, Kamat AM. Outcome of Patients with Micropapillary Bladder Cancer treated with Radical Cystectomy with/without Neoadjuvant Chemotherapy. American Urological Association 2015 Meeting, 2015.
50. Siefker-Radtke AO, Choi W, Porten SP, Shen Y, Kamat AM, Matin SF, Dinney C PN, Czerniak B, McConkey DJ. The basal subtype predicts clinical benefit from neoadjuvant chemotherapy: Final results from a phase II clinical trial of DDMVAC plus bevacizumab. J Clin Oncol 33(suppl 7; abstr 291), 2015.
51. Williams ST, Fernandez M, Willis DL, Slack R, Siefker-Radtke AO, Navai N, Dickstein RJ, Guo C, Czerniak B, McConkey DJ, Parikh S, Pisters L, Shah JB, Grossman HB, Dinney CP, Kamat AM. Risk group stratification in patients with micropapillary bladder cancer treated with radical cystectomy and/or neoadjuvant chemotherapy. J Clin Oncol 33(suppl 7; abstr 302), 2015.
52. Mmeje, CH, Benson, C, Nogueras-Gonzalez GM, Jayaratna IS, Navai N, Gao J, Siefker-Radtke AO, Kamat AM, Dinney CP, Shah JB. Determining the optimal timing for radical cystectomy after neoadjuvant chemotherapy. J Clin Oncol 33(suppl 7; abstr 339), 2015.
53. Ho PL, Willis DL, Patil J, Tart K, Parikh S, Shah JB, Delacroix SE, Siefker-Radtke AO, Dinney CP, Pisters LL, Kamat AM,. Outcome of patients with clinically node-positive bladder cancer who undergo consolidative surgery after preoperative chemotherapy: MD Anderson Cancer Center experience. 2014 Genitourinary Cancers Symposium, 2014.
54. Siefker-Radtke AO, Choi W, Melquist J, Shen Y, Kamat A, Matin S, Millikan R, Dinney CP, Czerniak BA, McConkey DJ. Gene expression profiling in the context of neoadjuvant chemotherapy with DDMVAC+B (dose dense methotrexate, vinblastine, doxorubicin, cisplatin, and bevacizumab) can predict clinical outcomes and tumor biology. AACR 2014 Meeting, 2014.
55. Porten SP, Siefker-Radtke AO, Kamat AM, Dinney CPN, Matin SF. Survival outcomes in patients undergoing neoadjuvant chemotherapy for upper tract urothelial cell carcinoma. 2013 ASCO GU Symposium, 2013.
56. Willis DL, Fernandez M, Dickstein RJ, Parikh S, Siefker-Radtke AO, Guo C, Czerniak B, Shah JB, Pisters LL, Grossman HB, Dinney CPN, Kamat AM. Outcome of patients with micropapillary bladder cancer treated with neoadjuvant therapy and radical cystectomy. 2013 ASCO GU Symposium, 2013.
57. Pagliaro LC, Munsell MF, Harris D, Carolla RL, Siefker-Radtke AO. Gemcitabine, paclitaxel, and doxorubicin as first-line therapy for patients with advanced urothelial carcinoma and renal insufficiency: A phase II study. 2013 ASCO Annual Meeting, 2013.
58. Siefker-Radtke AO, Wen S, Shen Y, Stigall K, McConkey DJ, Millikan RE. A novel phase I trial design featuring a two-dimensional dose-finding algorithm optimizing the dose of gemcitabine and doxorubicin with bortezomib in metastatic urothelial carcinoma (UC). 2013 ASCO Annual Meeting, 2013.
59. Dinney CPN, Choi W, Porten SP, Roth B, Cheng T, Willis DL, Tran MN, Lee IC, Bondaruk JE, Majewski T, Zhang S, Pretzsch SM, Baggerly KA, Siefker-Radtke AO, Czerniak B, McConkey DJ. A STAT3- and p63-dependent transcriptional network to define a lethal basal subset of human bladder cancers. 2013 ASCO Annual Meeting, 2013.
60. Porten SP, Gopalakrishnan V, Nogueras-Gonzalez GM, Kamat AM, Siefker-Radtke AO, Dinney CPN, Matin SF. Survival of upper tract urothelial carcinoma: A population-based analysis. 2013 Genitourinary Cancers Symposium, 2013.
61. PortenS, Siefker-Radtke AO, Kamat A, Dinney C, Matin S. Survival outcomes in patients undergoing neoadjuvant chemotherapy for upper tract urothelial cell carcinoma. American Urological Association 2013 Meeting, 2013.
62. Siefker-Radtke AO, Kamat AM, Corn PG, Matin SF, Grossman HB, Millikan RE, Dinney CPN. Neoadjuvant chemotherapy with DD-MVAC and bevacizumab in high-risk urothelial cancer: Results from a phase II trial at the M. D. Anderson Cancer Center. 2012 ASCO GU Symposium, 2012.
63. Siefker-Radtke AO, Kamat AM, Corn PG, Matin SF, Grossman HB, Millikan RE, Dinney CPN. Neoadjuvant chemotherapy with DD-MVAC and bevacizumab in high-risk urothelial cancer: Results from a phase II trial at the University of Texas M. D. Anderson Cancer Center. 2012 ASCO Annual Meeting, 2012.
64. Dayyani F, Munsell MF, Siefker-Radtke AO. Incidence of peritoneal carcinomatosis in recurrent plasmacytoid urothelial carcinomas (PUC) of the bladder: A retrospective analysis of patient outcomes at M. D. Anderson Cancer Center (MDACC). 2012 ASCO Annual Meeting, 2012.
65. Grivas P, Agarwal N, Siefker-Radtke, AO, Daignault S, Puzanov I, MacVicar GR, Levine EG, Srinivas S, Twardowski P, Eisenberger MA, Quinn DI, Vaishampayan UN, Yu EY, Dawsey S, Day KC, Day ML, Smith DC, Hussain M. Randomized phase II trial of gemcitabine/cisplatin (GC) with or without cetuximab (CET) in patients (pts) with advanced urothelial carcinoma (UC). 2012 ASCO Annual Meeting, 2012.
66. Navai N, Williams MB, Wen S, Siefker-Radtke AO, McConkeyDJ, Dinney CPN, Adam L. Relationship between high microRNA-200C expression and the risk of death from disease in muscle-invasive urothelial carcinoma of the bladder. 2012 Genitourinary Cancers Symposium, 2012.
67. Aparicio A, Sun J, Tang DN, Arap W, Araujo J, Corn P, Tannir N, Wang X, Siefker-Radtke AO, Sharma P. A phase II study of ipilumimab plus androgen deprivation therapy in castraton-sensitive prostate carcinoma. AACR 2012 meeting, 2012.
68. Choi W, Shah JB, Tran M, Svatek RS, Marquis L, Lee IC, Yu D, Adam L, Bondaruk JE, Wen S, Shen Y, Dinney CPN, Czerniak B, McConkey DJ, Siefker-Radtke AO. Use of P63 expression to define a lethal subset of muscle-invasive bladder cancers. 2011 ASCO Annual Meeting, 2011.
69. Pagliaro LC, Munsell M, Harris D, Carolla RL, Siefker-Radtke AO. Gemcitabine, paclitaxel and doxorubicin for patients (pts) with urothelial carcinoma (UC) and renal insufficiency: Preliminary results of a multicenter phase II study. 2011 ASCO GU Symposium, 2011.
70. Siefker-Radtke AO, Margulis V, Kamat A, Grossman B, Wood C, Millikan R, Dinney C, Matin S. Evidence for neoadjuvant chemotherapy for high-grade upper-tract urothelial cancer: a retrospective review from the M. D. Anderson Cancer Center. 2010 ASCO GU Symposium(282), 2010.
71. Alva As, Agarwal N, Siefker-Radtke AO, Roth BJ, Smith DC, Daignault S, Srinivas S, Bradley DA, Hussain M. Targeting epidermal growth factor receptor (EGFR) in urothelial cancer (UC): A phase II randomized trial of cisplatin (C) with gemcitabine (G) with or without cetuximab. 2010 ASCO Annual Meeting, 2010.
72. Lynch SP, Vu TT, Kamat, AM, Grossman HB, Millikan RE, Dinney CP, Siefker-Radtke AO. The Impact of neoadjuvant chemotherapy in small cell carcinoma of the bladder: The MD Anderson Cancer Center experience. 2010 ASCO Annual Meeting, 2010.
73. Shah JB, Marquis LM, Svatek RS, Papadopoulos JN, Siefker-Radtke AO, Dinney CP, McConkey DJ. The mitiotic spindle apparatus inhibitor AZD4877 holds promise as a novel therapeutic option against human bladder cancer. 2009 ASCO GU Symposium, 2009.
74. Siefker-Radtke AO, Kamat AM, Williams DL, Tannir NM, Tu S, Pagliaro LC, Dinney CP, Millikan RE. A phase II randomized 4-regimen selection trial incorporating response for sequential chemotherapy in metastatic, unresectable urothelial cancer: Final results from M. D. Anderson Cancer Center. 2009 ASCO GU Symposium, 2009.
75. Nguyen JM, Shah JB, Svatek RS, Siefker-Radtke AO, Dinney CP, McConkey DJ. The SRC inhibitor AZD0530 induces growth inhibition and migratory arrest of human bladder cancer cell lines. 2009 ASCO GU Symposium, 2009.
76. Chiong E, Taylor JM, Siefker-Radtke AO, Millikan RE, Urbauer D, McConkey DJ, Grossman HB, Dinney CP, Kamat AM. Micropapillary bladder cancer: comparison of outcomes with up front cystectomy and neoadjuvant chemotherapy. 2009 ASCO GU Symposium, 2009.
77. McConkey DJ, Svatek R, Siefker-Radtke AO, Choi W, Shah J, Das A, Kwan A, Adam L, Dinney CP. HDAC inhibitors reverse epithelial-to-mesenchymal transition (EMT) and restore sensitivity to EGFR inhibitors in urothelial carcinoma cells. 2009 ASCO GU Symposium, 2009.
78. Siefker-Radtke AO. A phase II randomized for-regimen selection trial incorporating response for sequential chemotherapy in metastatic, unresectable urothelial cancer: Final results from the MD Anderson Cancer Center. 2009 ASCO Annual Meeting, 2009.
79. Siefker-Radtke AO. A phase II randomized 4-regimen selection trial incorporating response for sequential chemotherapy in metastic, unresectable urothelial cancer: Final results from the MD Anderson Cancer Center. 2009 ASOC GU Symposium, 2009.
80. Siefker-Radtke AO, Millikan RE, Kamat AM, Shen Y, Williams DL, Grossman HB, Dinney CP. A phase II trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine (IAG), followed by cisplatin, gemcitabine and ifosfamide (CGI) in locally advanced urothelial cancer (UC): final results from the M. D. Anderson Cancer Center. 2008 ASCO Annual Meeting 26(15S):269s, 2008.
81. Agarwal PK, Kassouf W, Grossman HB, Munsell MF, Siefker-Radtke AO, Pisters LL, Dinney CP, Kamat AM. Outcome of bladder cancer patients with pN+ disease after preoperative chemotherapy and radical cystectomy. 2008 ASCO GU Symposium, 2008.
82. Siefker-Radtke AO, Kamat AM, Grossman H, Williams Dl, Dinney CP, Millikan RE. Final results from a phase II trial of systemic chemotherapy in small cell urothelial cancer: evidence supporting neoadjuvant chemotherapy from the M. D. Anderson Cancer Center. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part 1 25(18S), 2007.
83. Siefker-Radtke AO, Mathew P, Tannir NM, Tu S, Logothetis CL, Papandreou C. Phase I study of weekly intravenous bortezomib plus mitoxantrone in patients with androgen-independent prostate cancer. American Association of Cancer Research Innovations in Prostate Research, 2006.
84. Zhu K, Pino S,Siefker-Radtke AO, Shalinsky D, Hu-Lowe D, McConkey DJ. AG-013736, a novel VEGF receptor and PDGF receptor inhibitor with potent activity against human bladder carcinoma in vitro and in vivo. J Clin Oncol 24(18S):13109, 2006.
85. Rodney AJ, Siefker-Radtke AO, Tannir NM, Swisher S, Walsh G, Millikan RE, Pagliaro LC. Treatment outcomes of patients (pts) with primary mediastinal germ cell tumors (PMGCT): The M. D. Anderson Cancer Center (MDACC) experience. J Clin Oncol 24(18S):14538, 2006.
86. Brown GA, Spiess PE, Bassett RL, Siefker-Radtke AO, Grossman HB, Dinney CP, Kamat AM. Management of primary carcinomas of the male urethra. American Urological Association Annual Meeting, 2006.
87. Siefker-Radtke AO, Kamat AM, Grossman HB, Williams DL, Dinney CP, Millikan RE. Prospective evidence supporting the utility of neoadjuvant chemotherapy in small cell urothelial cancer: preliminary results from a phase II clinical trial at the M. D. Anderson Cancer Center. American Urological Association Annual Meeting, 2006.
88. Jonasch E, Tu SM, Tannir NM, Pagliaro LC, Mathew P, Siefker-Radtke AO, Wen S, Wen S, General R, Lin SH, Logothetis CJ. Bone-targeted therapy consisting of zoledronate, thalidomide, and gamma interferon in renal cell carcinoma; a phase II study. J Clin Oncol 23(16S), 2005.
89. Siefker-Radtke AO, Poulter V, Mathew P, Tu S, Logothetis C , Papandreou C. Preliminary evidence of efficacy and tolerance for weekly intravenous bortezomib plus mitoxantrone in patients with advanced androgen-independent prostate cancer (AIPCa). J Clin Oncol 23(16S):4567, 2005.
90. McConkey DJ, Papageorgiou A, Lashinger L, Shrader M, Zhu K, Millikan R, Adam L, Bar-Eli M, Siefker-Radtke AO, Dinney CP. Death receptor-based combination therapy in preclinical models of human bladder cancer. 13th SPORE Workshop, 2005.
91. Siefker-Radtke AO, Thall PF, Tannir NM, Tu S, Pagilaro LC, Williams DL, Millikan RE. Implementation of a novel statistical design to evaluate successive treatment course for metastatic transitional cell carcinoma. A Phase II trial at the M. D. Anderson Cancer Center. J Clin Oncol 23(14S):391, 2004.
92. Tannir NM, Cohen L, Wang X, Ng C, Poulter V, Mathew P, Siefker-Radtke AO, Jonasch E, Pagilaro L, Thall PF, Millikan RE, Logothetis C. A randomized phase III trial of low dose versus intermediate dose interferon alfa (IFN) as front-line therapy in advanced progressive renal cell cancer (RCC). J Clin Oncol 22(14S):407, 2004.
93. Abrahams NA, Siefker-Radtke AO, Reyes AO, Ayala AG, Moran CA. Small cell carcinoma of the bladder: A contemporary clinicopathologic study of 51 cases, 2004.
94. Sweeny P, Millikan R, Donat M, Wood CG Wood, Siefker-Radtke AO, Pettaway CA, Grossman, HB, Dinney CPN, Swanson DA, Pisters LL. Is there a therapeutic Role for Post-Chemotherapy retroperitoneal Lymph node dissection in metastatic transitional cell carcinoma of the bladder?. Journal of Urology 169(6):2113-2117, 2003.
95. Siefker-Radtke, A, Gee, J, Logothetis, C, Millikan, R. Is there an effective chemotherapy in the treatment of metastatic urachal carcinoma? The M. D. Anderson Experience. Proc Am Soc Clin Oncol 21:2496, 2002.
96. Siefker-Radtke, A, Walsh, G, Swanson, D, Logothetis, C, Millikan, R. Is there a role for surgery in the management of metastatic urothelial cancer? An update of the M. D. Anderson Experience. J Urology 167(4):Abstract # 1116, 2002.
97. Siefker-Radtke AO, Walsh G, Swanson D, Logothetis C, Millikan R. Is There a Role for Surgical Resection in the Management of Metastatic Urothelial Cancer? The M. D. Anderson Experience. Proc Am Soc Clin Oncol 20: 2001 20, 2001.
98. Siefker-Radtke AO, Dinney CP, Abrahams N, Moran C, Pisters L, Grossman HB, Swanson DA. Is there a role for pre-operative chemotherapy in small cell bladder carcinoma? The M. D. Anderson experience. J Urology 169(4), 2000.

Book Chapters

1. Dietrich B, Siefker-Radtke AO, Srinivas S, Yu EY. Systemic Therapy for Advanced Urothelial Carcinoma: Current Standards and Treatment Considerations. In: Am Soc Clin Oncol Educ Book. 38. ASCO, 342-353, 2018.
2. Al-Shamsi, Hansel DE, Siefker-Radtke AO. Uncommon Cancers of the Bladder. In: Textbook of Uncommon Cancer. 5th. Wiley-Blackwell, 41-53, 2017.
3. Siefker-Radtke AO, Czerniak BA, Dinney CPN, McConkey DJ.. Bladder Cancer. In: In: The MD Anderson Manual of Medical Oncology. 3rd. McGraw-Hill Education, 755-773, 2016.
4. SiefkerRadtke, AO. Urachal and Non-Urachal Adenocarcinomas of the Bladder. In: Rare Genitourinary Tumors. Springer International Publishing Switzerland, 2016.
5. Balar A, Tagawa ST, Galsky M, Siefker-Radtke AO. Chemotherapy. In: Upper Tract Urothelial Carcinoma. Springer: New York, 2015.
6. McConkey DJ, Woonyoung C, Ochoa A, Siefker-Radtke AO, Bogdan C, Czerniak B, Dinney CPN. Therapeutic Opportunities in the Intrinsic Subtypes of Muscle-Invasive Bladder Cancer. In: Bladder Cancer, 2015.
7. Siefker-Radtke AO, Dinney CP, Czerniak B, Millikan RE. Bladder Cancer. In: The MD Anderson Manual of Medical Oncology. 3rd. McGraw-Hill, 2015.
8. Siefker-Radtke AO. Targeted Therapy in Urothelial Cancer. In: Handbook of Targeted Cancer Therapy. Wolters Kluwer Health: USA, 2015.
9. Siefker-Radtke AO. Targeted Therapy in Urothelial Cancer. In: Handbook of Targeted Cancer Therapy. Wolters Kluwer Health: USA, 2014.
10. Svatek RS, Kamat AM, Siefker-Radtke AO, Dinner CPN. Bladder Cancer. In: 60 Years of Survival Outcomes at The University of Texas M. D. Anderson Cancer Center. Springer, 2012.
11. Ng C, Siefker-Radtke AO, Kamat A. Bladder Cancer and Upper Tracts. In: Oncologic Imaging: A Multidisciplinary Approach. Elsevier: Philadelphia, 311 - 333, 2012.
12. Siefker-Radtke A. Chemotherapy, Surgical and Radiation Options for Metastatic Bladder Cancer. In: Essentials and Updates in Urinary Oncology. Nova Science: USA, 2012.
13. Parwani A, Dinney C, Siefker-Radtke A. Small Cell Urothelial Carcinoma. In: The Urinary Tract. Springer Publishers, 2012.
14. Siefker-Radtke AO, Czerniak B, Dinney C, Millikan RE. Uncommon Cancers of the Bladder. In: Textbook of Uncommon Cancer. 4th. John Wiley and Sons, 2012.
15. Efstathiou J, Quinn DI, Stenzl A, Bellmunt J, Cookson MS, Gakis G, Guru K, Heidenreich A, Keegan P, Lerner SP, Messing EM, Sagalowsky AI, Schoenberg MP, Shipley WU, Siefker-Radtke. Muscle-invasive, Presumably Regional, Tumor. In: Bladder Cancer. Second Edition. European Association of Urology: France, 269 - 342, 2012.
16. Siefker-Radtke, AO, Dinney CPN, Czerniak, B, Millikan RE. Bladder Cancer. In: The MD Anderson Manual of Medical Oncology. 2nd. McGraw Hill Medical, 925 - 943, 2011.
17. Siefker-Radtke AO, Dinney CP, Czerniak B, Millikan RE. Bladder Cancer. In: The MD Anderson Manual of Medical Oncology. 1st. McGraw-Hill, 739-756, 2006.
18. Siefker-Radtke AO, Czerniak B, Dinney C, Millikan RE. Uncommon Cancers of the Bladder. In: Textbook of Uncommon Cancer. 3rd ed. John Wiley and Son, 2006.